{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+5",
    "query": {
      "intervention": "Placebo, Cohort 5"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 616,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+5&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T00:14:38.397Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07229911",
      "title": "A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "TAK-781",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 134,
      "start_date": "2026-01-07",
      "completion_date": "2028-04-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07229911"
    },
    {
      "nct_id": "NCT06200597",
      "title": "A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "LAD603",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Almirall, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 92,
      "start_date": "2023-12-05",
      "completion_date": "2025-05-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06200597"
    },
    {
      "nct_id": "NCT04167553",
      "title": "Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obese With Comorbidities",
        "Overweight With Comorbidities",
        "Type2 Diabetes"
      ],
      "interventions": [
        {
          "name": "HM15136",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2019-08-30",
      "completion_date": "2020-12-09",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04167553"
    },
    {
      "nct_id": "NCT01044537",
      "title": "A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2010-02",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Cypress, California • Miami, Florida",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01044537"
    },
    {
      "nct_id": "NCT05698095",
      "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Safety",
        "Tolerability"
      ],
      "interventions": [
        {
          "name": "5-methoxy-N,N-dimethyltryptamine succinate salt",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Usona Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2022-12-27",
      "completion_date": "2023-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05698095"
    },
    {
      "nct_id": "NCT06138795",
      "title": "A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD2389",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2023-11-20",
      "completion_date": "2025-08-24",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06138795"
    },
    {
      "nct_id": "NCT02185794",
      "title": "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "Voxilaprevir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match voxilaprevir",
          "type": "DRUG"
        },
        {
          "name": "SOF/VEL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 101,
      "start_date": "2014-06-13",
      "completion_date": "2015-09-28",
      "has_results": true,
      "last_update_posted_date": "2020-09-17",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 10,
      "location_summary": "Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02185794"
    },
    {
      "nct_id": "NCT01959594",
      "title": "A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "3 mg PF-06412562",
          "type": "DRUG"
        },
        {
          "name": "10 mg PF-06412562",
          "type": "DRUG"
        },
        {
          "name": "25 mg PF-06412562",
          "type": "DRUG"
        },
        {
          "name": "PF-06412562 TBD mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-11",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-28",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01959594"
    },
    {
      "nct_id": "NCT02234570",
      "title": "Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neurocysticercosis"
      ],
      "interventions": [
        {
          "name": "Oxfendazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 70,
      "start_date": "2014-11-17",
      "completion_date": "2015-11-24",
      "has_results": true,
      "last_update_posted_date": "2020-11-02",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234570"
    },
    {
      "nct_id": "NCT04569786",
      "title": "Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronavirus Disease (COVID-19)"
      ],
      "interventions": [
        {
          "name": "V590",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2020-10-29",
      "completion_date": "2021-02-18",
      "has_results": true,
      "last_update_posted_date": "2021-12-29",
      "last_synced_at": "2026-09-24T00:14:38.397Z",
      "location_count": 7,
      "location_summary": "Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04569786"
    }
  ]
}